SREBF1 and hyperlipidemia: In conclusion, our investigation showed that octacosanol could ameliorate hyperlipidemia in the HFD-induced mouse model, and the lipid-lowering function was mediated by multiple pathways, including AMPK/SREBP-1c/ACC, AMPK/SIRT1, PPARs, and LXR pathways.